Precision BioSciences
DTIL
128 hedge funds and large institutions have $313M invested in Precision BioSciences in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 14 closing their positions.
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
45% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 31
36% more capital invested
Capital invested by funds: $231M → $313M (+$82M)
8% more funds holding
Funds holding: 118 → 128 (+10)
0.01% more ownership
Funds ownership: 1.76% → 1.77% (+0.01%)
6% less call options, than puts
Call options by funds: $1.24M | Put options by funds: $1.32M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$29.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.34M |
| 3 |
Morgan Stanley
New York
|
+$4.57M |
| 4 |
Citigroup
New York
|
+$4.17M |
| 5 |
Rafferty Asset Management
New York
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$14.9M |
| 2 |
WHAM
Windmill Hill Asset Management
Waddesdon,
United Kingdom
|
-$6.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.43M |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$2.73M |
| 5 |
CA
CHI Advisors
New York
|
-$1.88M |
DTIL Hedge Fund Activity: Q1 2021 in Review
128 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q1 2021, worth a combined $313M — up 36% from $231M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new DTIL positions and 14 closed out — a net gain of 11 holders — while 45 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $29.9M. The largest seller was Citadel Advisors, cutting an estimated $14.9M.
- 128 institutional investors held Precision BioSciences (DTIL) as of Q1 2021, up from 118 in Q4 2020.
- Funds reported $313M of Precision BioSciences stock for Q1 2021, up 36% quarter-over-quarter.
- 25 funds opened new Precision BioSciences positions in Q1 2021 and 14 closed out, a net change of +11 holders.
- The largest Precision BioSciences buyer in Q1 2021 was State Street, an estimated $29.9M added.
- The largest Precision BioSciences seller in Q1 2021 was Citadel Advisors, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2021.